A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Moderate to Severe Ulcerative Colitis

The primary Objective for the Induction Phase is to determine the effect of MLN0002 induction treatment on clinical response at 6 weeks. The primary Objective for the Maintenance Phase is to determine the effect of MLN0002 maintenance treatment on clinical remission at 52 weeks.